European Psychiatry - Volume 41 - April 2017

51 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S8–S52 S47
S128
Are treatment gains maintained?
Long-term psychological
interventions for bordeline
personality disorder
K. Lieb ∗, O.J. Storebø , B. Völlm , J. Mattivi , S. Nielsen ,
M. Kielsholm , E. Simonsen , J. Stoffers-Winterling
1 University Medical Center of the Johannes Gutenberg University
Mainz, Department of Psychiatry and Psychotherapy, Mainz,
Germany
2 Pychiatric Research Unit, Psychiatric Department- Region Zealand,
Slagelse, Denmark
3 Section of Forensic Mental Health, Department of Psychiatry and
Applied Psychology- Section of Forensic Mental Health, Nottingham,
United Kingdom
4 University of Copenhagen Institute of Clinical Medicine, Psychiatry-
Region Zealand, Slagesle, Denmark
∗ Corresponding author.
Introduction Many new approaches have been developed to
treat borderline personality disorder (BPD) by means of psy-
chotherapy. Though there is a clear research trend towards
short-interventions, the evidence from randomised controlled tri-
als (RCT) on longer-term programmes still accumulates. On the
one hand, well-established treatments like Dialectical Behavior
Therapy (DBT) or Mentalisation-Based Treatment (MBT) are now
subject to real-world effectiveness studies; on the other hand,
new dynamic approaches have been studied, lasting longer than
6 months.
Objectives We are currently updating the cochrane Collaboration
review on psychological interventions for BPD. First findings on the
effects of longer-term psychotherapies will be presented.
Methods We conducted a systematic reviewandmeta-analysis of
randomized controlled trials (RCTs) according to cochrane collab-
oration standards. Any randomized comparisons of psychological
interventions versus unspecific control interventions, waitlist or
specific psychotherapeutic interventions in adult BPD patients
were eligible. Primary outcomes were BPD core pathology as
depicted by DSM criteria. Secondary outcomes included associated
pathology, i.e., depression and anxiety, general psychopathology
severity and functioning as well as tolerability and safety. Two
researchers selected trials, assessed quality and extracted data
independently.
Results The current evidence of longer-term psychological inter-
ventions in general, and the types of interventions for which RCT
evidence is available will be evaluated and critically discussed.
Disclosure of interest The authors declare that they have no com-
peting interest.
S129
Do mood stabilizers help in borderline
personality disorder?
B. Völlm ∗, J. Stoffers-Winterling , J. Mattivi , E. Simonson ,
O.J. Storebø , S. Nielsen , M.L. Kielsholm , K. Lieb
1 Section Forensic Mental Health, Division of Psychiatry and Applied
Psychology, Nottingham, United Kingdom
2 University of Mainz Medical Center, Department of Psychiatry and
Psychotherapy, Mainz, Germany
3 Institute of Clinical Medicine- University of Copenhagen,
Psychiatry- Region Zealand, Slagelse, Denmark
4 Psychiatric Research Unit, Psychiatric Departement- Region
Zealand, Slagelse, Denmark
∗ Corresponding author.
Background Despite the relatively weak evidence base, individ-
uals with borderline personality disorder are often treated with
pharmacological interventions. Amongst the drugs, which have
shown most promise, are mood stabilizers, which were one of the
two drug classes with the most beneficial effects in a previous
cochrane review though the robustness of findings was described
as low (Stoffers et al., 2010). Here we present data on the latest evi-
dence for mood stabilizers based on an updated cochrane review
currently underway.
Methods A systematic review and meta-analysis of randomized
controlled trials was conducted. All randomized comparisons of
drug vs. placebo, drug vs. drug, or drug vs. a combination of drugs
in adult BPD patients were eligible for inclusion. Outcomes com-
prised BPD core pathology as depicted by DSM criteria, associated
pathology, i.e., depression and anxiety, general measures of over-
all psychopathology severity, tolerability, and adverse effects. Two
researchers selected trials, assessed quality and extracted data
independently.
Results Only a limited number of additional trials using mood
stabilizers was identified since the publication of the last cochrane
review, mainly utilizing Sodium Valproate. This added to the
evidence base for mood stabilizers though the overall evidence
remains very limited.
Conclusion Mood stabilizers show some initial evidence for their
effectiveness in borderline personality disorder. However, these
have to be replicated before wider conclusions can be drawn for
clinical practice.
Disclosure of interest The authors declare that they have no com-
peting interest.
S130
Effectiveness of antipsychotic
medication in the treatment of BPD
J. Stoffers-Winterling ∗, O.J. Storebø , B. Völlm , J. Mattivi ,
S. Nielsen , M.L. Kielsholm , E. Simonsen , K. Lieb
1 University Medical Center of the Johannes Gutenberg University
Mainz, Department of Psychiatry and Psychotherapy, Mainz,
Germany
2 Psychiatric Research Unit, Psychiatric Department Region Zealand,
Slagelse, Denmark
3 Division of Psychiatry and Applied Psychology University of
Nottingham, Section of Forensic Mental Health, Nottingham, United
Kingdom
4 University of Copenhagen Institute of Clinical Medicine, Psychiatry
Region Zealand, Slagelse, Denmark
∗ Corresponding author.
Introduction Though prescription is off-lable, “atypical” or
“second-generation” antipsychotics (SGAs) are prevalently given to
borderline personality disorder (BPD) patients. They have also been
the focus of research on pharmacological agents in BPD in recent
years, as the previous version of the relating cochrane systematic
review shows.
Objectives We are currently updating this cochrane system-
atic review on pharmacological interventions for BPD. First
findings on the up-to-date evidence relating to SGAs will be
presented.
Methods We conducted a systematic review and meta-analysis
of randomized controlled trials (RCTs) according to cochrane col-
laboration standards. Any randomized comparisons of drug vs.
placebo, drug vs. drug, or drug vs. a combination of drugs in
adult BPD patients were eligible. Primary outcomes were BPD
core pathology as depicted by DSM criteria. Secondary outcomes
included associated pathology, i.e., depression and anxiety, general
psychopathology severity and functioning as well as tolerability
and safety. Two researchers selected trials, assessed quality and
extracted data independently.
Results The current RCT evidence on SGAs in BPD will be pre-
sented, and their use in everyday clinical care settings will critically
be discussed.